Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ligand Pharmaceuticals Inc

LGND ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: STRONG BUY

Last Close

$288.83

▲ +1.13%

Market Cap $5.76B · Vol 53.70K

Key Metrics

P/E Ratio

30.72

FWD: 26.09

Market Cap

$5.76B

Mid Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+13.92%

YoY

RSI (14)

51.37

Momentum

Beta

1.20

vs Market

52W High

$324.99

11.13% below

52W Low

$161.91

78.39% above

Volume

53.70K

Avg 63.14K

P/B

3.68

Price-to-book

ROE

17.87%

Return on equity

Free Float

97.63%

Public shares

Shariah Compliance8 STANDARDS

✗ Ligand Pharmaceuticals Inc (LGND) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LGND pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.66%

-1.47%

+21.48%

+43.06%

YTD

+52.76%

+74.14%

+358.10%

+239.11%

Financials & Valuation

TTM · Annual

Total Revenue	$215.02M
Net Income	$124.45M
Revenue Growth (YoY)	+33.73%
Gross Margin	78.02%
Operating Margin	-0.59%
Net Profit Margin	57.88%
ROE	17.87%
ROA · ROIC	12.70% · 11.17%

P/E Ratio	30.72
Forward P/E (FY1)	26.09
PEG Ratio	0.01
P/S	17.85
P/B	3.68
P/FCF	78.45
EPS Growth	+13.92%
Outstanding Shares	19.94M

Technical Indicators

50-Day SMA	$297.23
200-Day SMA	$232.80
RSI (14)	51.37
Beta	1.20
52-Week High	$324.99
52-Week Low	$161.91

Volume Today	53.70K
Avg Daily Volume (30D)	63.14K
Relative Volume	0.85x
Volatility (10D)	18.84
Volatility (30D)	26.31
Free Float	97.63%

Analyst Consensus

STRONG BUY

Current Price $288.83

Mean Target $342.82

52W Low$161.91 52W High$324.99

Current

Target

$161.91 $324.99

Current Analyst target

+18.69% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S8CH99

ISINUS53220K5048

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.21% JNJ Johnson & Johnson -2.22% ABBV Abbvie Inc -2.99% NVS Novartis AG -13.93% NOVN.S Novartis AG -10.89%

Company Profile

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.